Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
If you’ve been researching GLP-1 medications, you may have noticed that Zepbound and Mounjaro look suspiciously similar. That’s because they contain the exact same active ingredient — tirzepatide — manufactured by Eli Lilly. So what’s actually different between them?
The Core Difference: Approved Indication
Mounjaro is approved by the FDA for type 2 diabetes management. It improves blood sugar control and many patients experience significant weight loss as a side effect.
Zepbound is approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure or sleep apnea.
Same Drug, Different Pricing
Because they’re approved for different indications, insurance coverage differs significantly. Mounjaro may be covered if you have a type 2 diabetes diagnosis, while Zepbound is billed under obesity/weight management benefits — which many plans historically haven’t covered.
Without insurance, both carry a list price around $1,000–$1,100/month. Eli Lilly offers savings cards for both that can dramatically reduce out-of-pocket costs for eligible commercially insured patients.
Dosing: Identical
Both Zepbound and Mounjaro come in the same doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg weekly injections. The titration schedule is the same — typically starting at 2.5mg for 4 weeks before stepping up.
Which Should You Ask About?
This really comes down to your diagnosis and insurance situation. Your doctor will prescribe whichever is most appropriate — and most likely to be covered. Some people with type 2 diabetes and obesity may be prescribed Mounjaro, while those without a diabetes diagnosis would typically receive Zepbound.
This article is for informational purposes only. Always consult your healthcare provider before starting any medication.
Zepbound vs. Mounjaro: Same Drug, Two FDA Approvals
One of the most common sources of confusion in the GLP-1 space is the relationship between Zepbound and Mounjaro. Both are manufactured by Eli Lilly and both contain tirzepatide as the active ingredient. The difference is entirely in their FDA approval: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition.
In clinical practice, this distinction affects insurance coverage far more than clinical outcomes — the medication itself is identical.
Zepbound vs. Mounjaro vs. Ozempic vs. Wegovy: 2026 Comparison
| Drug | Active Ingredient | FDA Approval | Avg. Weight Loss | List Price/Month |
|---|---|---|---|---|
| Zepbound | Tirzepatide | Weight management | 22.5% body weight | ~$1,060 |
| Mounjaro | Tirzepatide | Type 2 diabetes | ~21% body weight | ~$1,030 |
| Wegovy | Semaglutide | Weight management | ~15% body weight | ~$1,350 |
| Ozempic | Semaglutide | Type 2 diabetes | ~14% body weight | ~$970 |
Is Zepbound Worth the Cost in 2026?
For people who qualify and can access coverage, Zepbound represents the highest weight loss potential among currently FDA-approved medications. The 22.5% average body weight reduction from the SURMOUNT-1 trial is significant — for a 220-pound person, that is a potential loss of 49 pounds over 72 weeks.
The challenge remains cost. Without insurance covering weight management medications (still limited in many plans), the out-of-pocket expense of $1,000+/month is prohibitive for most people. Options to reduce cost include manufacturer savings programs through Eli Lilly and telehealth services that may offer compounded alternatives.
How to Get Zepbound Prescribed
To be prescribed Zepbound, patients typically need to meet criteria including a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as hypertension, type 2 diabetes, or sleep apnea. The prescription can come from:
- A primary care physician or obesity medicine specialist
- A telehealth provider specializing in weight management
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound are the same medication — tirzepatide — with different FDA indications. Mounjaro is approved for type 2 diabetes; Zepbound for weight management. Insurance coverage rules differ based on the indication.
Is Zepbound better than Wegovy?
Head-to-head trials comparing tirzepatide (Zepbound) directly to semaglutide (Wegovy) show tirzepatide produces greater weight loss on average. The SURMOUNT-5 trial demonstrated approximately 47% greater weight loss with tirzepatide versus semaglutide over 72 weeks.
📚 Related Reading
📖 Further Reading
Considering GLP-1 Medication for Weight Loss?
See if you qualify for compounded semaglutide — the affordable alternative to brand-name Ozempic — starting from $149/month. No insurance required.
Take the Free Eligibility Quiz →
Sponsored | Affiliate link | Not available in all states
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.